title: Intrapleural administration of gelatin-embedded, sustained-release basic fibroblast growth factor for the regeneration of emphysematous lungs in rats.
abstract: BACKGROUND
  Intra-airway and intra-arterial administration of gelatin-embedded, sustained-release basic fibroblast growth factor has stimulated regeneration of emphysematous lungs in animal experiments, but these routes of administration may also cause harm. This study investigated the effectiveness of intrapleural administration of gelatin-embedded, sustained-release basic fibroblast growth factor. This animal experiment preceded our clinical trial of intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax.
  
  
  METHODS
  Pulmonary emphysema was induced in Sprague-Dawley rats using porcine elastase. Gelatin-embedded, sustained-release basic fibroblast growth factor was administered via the left pleural cavity. The rats were divided into a group that received gelatin-embedded, sustained-release basic fibroblast growth factor (FGF(+) group, n = 6), and a group that did not (FGF(-)group, n = 6). Animals were sacrificed after 14 days, and the results were evaluated by histologic examination.
  
  
  RESULTS
  In the FGF(+) group, the mean linear intercept value of the alveolar septa was significantly shorter on the treated side than on the untreated side (65.1 ± 7.0 vs 114.4 ± 7.5 μm; P = .0005). There was no significant difference in the mean linear intercept value between the treated and untreated sides in the FGF(-) group.
  
  
  CONCLUSIONS
  Intrapleural administration of sustained-release basic fibroblast growth factor induced lung regeneration in rats with elastase-induced pulmonary emphysema.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan. Electronic address: mkawago@wakayama-med.ac.jp.
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Kawago
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshimasu
authors.affiliation: Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
authors.affiliation: Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
authors.forename: Masaya
authors.initials: M
authors.lastname: Yamamoto
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan.
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Hirai
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Minami Wakayama Medical Center, Tanabe, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kinoshita
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan.
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Okamura
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D004337:Drug Carriers; D004343:Drug Implants; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D005780:Gelatin; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D010196:Pancreatic Elastase; D035422:Pleural Cavity; D011656:Pulmonary Emphysema / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage; D012038:Regeneration / Q000187:drug effects*
chemical_list: D004337:Drug Carriers; D004343:Drug Implants; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D005780:Gelatin; D010196:Pancreatic Elastase